Real-world use of telavancin in the treatment of osteomyelitis

Saravolatz, Louis D.; Cleveland, Kerry O.; Rikabi, Khalid; Hassoun, Ali; Reilly, Joseph; Johnson, Leonard B.; Cedric,; Valenti, S; Szpunar, Susan

doi:10.1016/j.diagmicrobio.2019.05.011

Cited by 8 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, colistin may cause severe neuroand nephrotoxicity and is used only as a "last-resort" antibiotic [173]. Telavancin, another derivative of vancomycin, approved for MDR infections, especially for osteomyelitis treatment, leads to adverse effects, such as nausea, vomiting, diarrhea and metallic taste [174]. Oritavancin has less side effects compared to vancomycin and was found to be safe in patients with osteomyelitis even when administering multiple doses a day [175].…”

Section: Discussion and Further Insightsmentioning

confidence: 99%

An Update on Antimicrobial Peptides (AMPs) and Their Delivery Strategies for Wound Infections

Patrulea¹,

Borchard²,

Jordan³

2020

Preprint

View full text Add to dashboard Cite

Bacterial infections occur when wound healing fails to reach the final stage of healing, usually hindered by the presence of different pathogens. Different topical antimicrobial agents are used to inhibit bacterial growth due to antibiotic failure in reaching the infected site accompanied very often by an increased drug resistance and other side effects. In this review, we focus on antimicrobial peptides (AMPs), especially those with a high potential of efficacy against multidrug-resistant and biofilm-forming bacteria and fungi present in wound infections. Currently, different AMPs undergo preclinical and clinical phase to combat infection-related diseases. AMP dendrimers (AMPDs) have been mentioned as potent microbial agents. Various AMP delivery strategies, such as polymers, scaffolds, films and wound dressings, organic and inorganic nanoparticles, to combat infection and modulate the healing rate have been discussed as well. New technologies such as CRISPR-Cas are taken into consideration as potential future tools for AMP delivery in skin therapy.

show abstract

Section: Discussion and Further Insightsmentioning

confidence: 99%

An Update on Antimicrobial Peptides (AMPs) and Their Delivery Strategies for Wound Infections

Patrulea¹,

Borchard²,

Jordan³

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Three observational studies have been published regarding telavancin for the treatment of osteomyelitis and osteosynthesis-associated infections. These studies included 14 [66], 60 [67], and 32 [68] patients with osteomyelitis, of which 64%, 37%, and 15% had osteosynthesis material, respectively. In the first study, surgery was performed in 57% of patients (8/14), but this was not specified in the latter two.…”

Section: Telavancin In Infective Endocarditis and Osteomyelitismentioning

confidence: 99%

“…Clinical success, defined as resolved or improved infection, was 78%, 73%, and 92% with a median treatment duration of 58 days (9-66), 41 days (3-179), and 31.5 days (6-94), respectively. MRSA was the most frequently isolated pathogen (100%, 67%, and 57%, respectively) [66][67][68].…”

Section: Telavancin In Infective Endocarditis and Osteomyelitismentioning

confidence: 99%

New-Generation Antibiotics for Treatment of Gram-Positive Infections: A Review with Focus on Endocarditis and Osteomyelitis

Bloem

Bax

Yusuf

et al. 2021

JCM

View full text Add to dashboard Cite

Infective endocarditis, osteomyelitis, and osteosynthesis-associated infections are mostly caused by Gram-positive bacteria. They are often difficult to treat and are associated with a poor prognosis. In the past 20 years, nine antibiotic drugs with predominant activity against Gram-positive bacteria have been introduced and approved by the Food and Drug Administration or the European Medicines Agency: ceftaroline, daptomycin, telavancin, dalbavancin, oritavancin, linezolid, tedizolid, delafloxacin, and omadacycline. This narrative review aims to provide an overview on these antibiotics with a special focus on their use in infective endocarditis, osteomyelitis, and osteosynthesis-associated infections. Although some of these approved antibiotics are promising, they should not be used as first- or second-line therapy, awaiting more clinical data.

show abstract

“…However, colistin may cause severe neuroand nephrotoxicity and is used only as a "last-resort" antibiotic [203]. Telavancin, another derivative of vancomycin, has been approved for MDR infections, especially for osteomyelitis treatment, but it leads to adverse effects, such as nausea, vomiting, diarrhea, and metallic taste [204]. Oritavancin has fewer side effects than vancomycin and was found to be safe in patients with osteomyelitis even when administering multiple doses a day [205].…”

Section: Advantages Disadvantagesmentioning

confidence: 99%

An Update on Antimicrobial Peptides (AMPs) and Their Delivery Strategies for Wound Infections

2020

View full text Add to dashboard Cite

Bacterial infections occur when wound healing fails to reach the final stage of healing, which is usually hindered by the presence of different pathogens. Different topical antimicrobial agents are used to inhibit bacterial growth due to antibiotic failure in reaching the infected site, which is accompanied very often by increased drug resistance and other side effects. In this review, we focus on antimicrobial peptides (AMPs), especially those with a high potential of efficacy against multidrug-resistant and biofilm-forming bacteria and fungi present in wound infections. Currently, different AMPs undergo preclinical and clinical phase to combat infection-related diseases. AMP dendrimers (AMPDs) have been mentioned as potent microbial agents. Various AMP delivery strategies that are used to combat infection and modulate the healing rate—such as polymers, scaffolds, films and wound dressings, and organic and inorganic nanoparticles—have been discussed as well. New technologies such as Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated protein (CRISPR-Cas) are taken into consideration as potential future tools for AMP delivery in skin therapy.

show abstract

Real-world use of telavancin in the treatment of osteomyelitis

Cited by 8 publications

References 15 publications

An Update on Antimicrobial Peptides (AMPs) and Their Delivery Strategies for Wound Infections

An Update on Antimicrobial Peptides (AMPs) and Their Delivery Strategies for Wound Infections

New-Generation Antibiotics for Treatment of Gram-Positive Infections: A Review with Focus on Endocarditis and Osteomyelitis

An Update on Antimicrobial Peptides (AMPs) and Their Delivery Strategies for Wound Infections

Contact Info

Product

Resources

About